New milestone achieved in Astellas T-cell engager collaboration: In February 2025, Astellas advanced the second program to GLP toxicology studies, triggering a $5 million milestone payment to CytomX.

Elsewhere in the obesity space — Amgen has initiated Phase 3 trials of its obesity drug MariTide, one in overweight and obese people without diabetes and another one for people with diabetes.

Amgen has been in a holding pattern, posting a small loss of 1.8% while floating around $314.91. The stock also fell short of ...

Hickory Point Bank & Trust acquired 1,064 shares of Amgen, valued at $277,000, during the fourth quarter. Institutional ...

The neurotransmitter glutamate is essential for regulating everything from mood to memory, but it can also encourage a toxic buildup of protein, which can contribute to Alzheimer's and related ...

Amgen's new research and development facility in San Francisco. (courtesy photo) Amgen shares saw a slight uptick on March 5 as the company shared the news that it has started two critical late-stage ...

We recently compiled a list of the 11 Best Undervalued Stocks to Invest in Now. In this article, we are going to take a look ...

Amgen’s most advanced obesity asset MariTide is entering Maritime—that is, a phase 3 program that includes two freshly ...

We know that weight loss drugs have been big winners for the companies that produce them. And now, biotech stock Amgen (AMGN) ...

MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and ...

Celltrion has received permission from the Food and Drug Administration for Stoboclo (CT-P41, denosumab-bmwo) and Osenvelt ...

Novo Nordisk launched NovoCare Pharmacy, to deliver doses of its weight-loss Wegovy drug directly to its users, in a bid to reduce its cost. The Danish pharmaceutical company said Wednesday that the ...